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A b s t r a c t
The dynamic evolution of therapeutic options including the use of vitamin K antagonists (VKA), non-vitamin K oral anticoagu-
lants (NOAC), more potent antiplatelet drugs as well as new generation drug-eluting stents could lead to the view that the current 
recommendations on the management of patients with percutaneous coronary intervention (PCI) requiring oral anticoagulation do 
not keep up with the results of several clinical studies published within the last 5 years. In the present overview, we summarize the 
recent advances in antithrombotic management used in atrial fibrillation patients undergoing PCI for stable coronary artery disease 
or acute coronary syndrome (ACS). The safety and efficacy of prasugrel and ticagrelor taken with oral anticoagulants also remain to 
be established in randomized trials; therefore the P2Y
12 inhibitor clopidogrel on top of aspirin or without is now recommended to 
be used together with a VKA or NOAC. It is still unclear which dose of a NOAC in combination with antiplatelet agents and different 
stents should be used in this clinical setting and whether indeed NOAC are safer compared with VKA in such cardiovascular patients. 
Moreover, we discuss the use of anticoagulation in addition to antiplatelet therapy for secondary prevention in patients with ACS. 
To minimize bleeding risk in anticoagulated patients following PCI or ACS, the right agent should be prescribed to the right patient 
at the right dose and supported by regular clinical evaluation and laboratory testing, especially assessment of renal function when 
a NOAC is used.
Key words: percutaneous coronary intervention, antiplatelet therapy, atrial fibrillation, non-vitamin K oral anticoagulants, vita-
min K antagonist.
Introduction
The coexistence of coronary artery disease (CAD) re-
quiring revascularization and thromboembolic disorders 
requiring oral anticoagulation (OAC) is a  common and 
complex clinical issue. The most frequent indication for 
OAC is atrial fibrillation (AF) [1]. The incidence of percuta-
neous coronary intervention (PCI) or coronary artery by-
pass surgery (CABG) in patients with AF is about 20% [2]; 
thus in Europe 1–2 million AF patients who are on OAC 
may require revascularization. Based on the results of 
a meta-analysis involving 120,566 patients with ST-seg-
ment elevation myocardial infarction (STEMI) or non-ST-
segment elevation myocardial infarction (NSTEMI) [3], 
AF was present in 7.5% of the overall study population 
and was associated with a  higher 7-day mortality rate 
of 5.1% compared with 1.6% for those without AF. In 
multivariable analysis AF was also associated with 2.4 
times for STEMI and 1.7 times for NSTEMI higher risk of 
long-term mortality between day 8 and 1 year. Accord-
ing to the results of subanalysis of the HORIZONS-AMI 
(Harmonizing Outcomes with Revascularization and 
Stents in Acute Myocardial Infarction) trial comparing 
different modern antithrombotic regimens and stents 
[4], patients with new-onset AF during STEMI had higher 
3-year rates of mortality (11.9% vs. 6.3%, p = 0.01), re-
infarction (16.4% vs. 7.0%, p < 0.0001), stroke (5.8% vs. 
1.5%, p < 0.0001), and major bleeding (20.9% vs. 8.2%, 
p < 0.0001). Moreover, recently the combination of 
reduced doses of non-vitamin K oral anticoagulants 
(NOAC), or direct oral anticoagulants (DOAC), with dual 
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antiplatelet therapy (DAPT), has been tested in patients 
after acute coronary syndrome (ACS). 
The dynamic evolution of therapeutic options in-
cluding the use of vitamin K antagonists (VKA), NOAC, 
more potent antiplatelet drugs as well as new generation 
drug-eluting stents (DES) could lead to the view that the 
current recommendations on the management in this 
group of patients do not keep up with the recent advanc-
es of modern pharmaco-invasive medicine [1, 5–7]. In the 
present overview, we summarize the current status of 
antithrombotic management in AF patients undergoing 
PCI for stable CAD or ACS. 
Peri-procedural antithrombotic management
Periprocedural management both in stable CAD and 
ACS patients on OAC remains a challenge. It requires the 
balance of the risk of thromboembolic complications, 
intracoronary thrombosis associated with anticoagula-
tion interruption and the risk of periprocedural bleeding 
related to the bridging anticoagulation and antiplatelet 
therapy [8–10]. Regardless of the type of chronic anti-
coagulation therapy, in patients on OAC, during PCI for 
both ACS and stable CAD, i) radial access should be the 
default to minimize the risk of access-related bleeding, 
ii) new generation DES or bare metal stents (BMS) are 
recommended if triple therapy is planned, iii) routine use 
of ticagrelor or prasugrel is discouraged because of their 
unknown safety profile in association with VKA or NOAC, 
and iv) GP IIb/IIIa inhibitors should be avoided unless for 
bail-out situations.
For many years, bridging therapy with parenteral hep-
arins instead of the uninterrupted treatment with VKA 
has been applied during PCI. The bridging strategy ratio-
nale was based on the replacement of oral warfarin by 
parenteral agents of short half-life, of rapid onset of their 
action during the procedure, and a relative easy strategy 
to reverse anticoagulant effects. However, for this empir-
ical approach there is a lack of robust evidence based on 
randomized, controlled studies. 
There is no doubt that in patients on OAC undergo-
ing PCI, the risk stratification of thrombosis and bleeding 
needs to be weighed first. However, existing scores such 
as CHA2DS2-VASC and HAS-BLED have not been validated 
in case of anticoagulation interruption or potential bridg-
ing therapy. In the prospective multicenter AFCAS (Atrial 
Fibrillation undergoing Coronary Artery Stenting) registry, 
bleeding complications and major adverse cardiac and 
cerebrovascular events (MACCE) including death, myo-
cardial infarction (MI), target vessel revascularization, 
stent thrombosis and stroke have been assessed during 
a 30-day follow-up period in 290 patients treated with 
uninterrupted OAC with VKA and in 161 patients with 
bridging therapy (BT) conducted for a median of 3 days 
before coronary artery stenting [11]. The international 
normalized ratio (INR) before PCI was higher (2.3 vs. 1.8, 
p < 0.001) and radial access was more common (43% vs. 
14%, p < 0.001) in the uninterrupted OAC group. In the BT 
periprocedural unfractionated or low-molecular weight 
heparin (LMWH) bolus (70% vs. 48%, p < 0.001) and gly-
coprotein IIb/IIIa inhibitors (26% vs. 7%, p < 0.001) were 
given more often as compared with the uninterrupted 
OAC group. Aspirin was started not later than during PCI 
in almost all patients, and less than 2% of patients in 
both groups did not receive periprocedural clopidogrel. 
Finally, at discharge triple therapy of aspirin, clopidogrel 
plus OAC and/or LMWH was the most frequent regimen 
after PCI in both BT and uninterrupted OAC groups (76% 
 vs. 90%, p < 0.001). On the other hand, dual therapy with 
clopidogrel plus OAC and/or LMWH was used in 6% of 
uninterrupted OAC and 12% of BT (p < 0.001). The length 
of hospitalization after PCI was longer in the BT group 
both in elective and in acute patients (3.2 vs. 1.9 days 
and 7.0 vs. 5.3 days, respectively; p < 0.05 for both). Over-
all bleeding complications tended to be more common in 
the BT group (19% vs. 12%, p = 0.07), with no significant 
difference in the rate of major bleeding (2.5% vs. 1.4%) or 
MACCE (6.2% vs. 3.8%). However, after propensity adjust-
ment, the frequency of bleeding complications or MACCE 
was similar. Multivariate analysis showed that femoral 
access, ACS and history of bleeding were independent 
predictors of bleeding complications and that ACS was 
the only independent predictor for MACCE. Periprocedur-
al INR was not associated with bleeding or MACCE. The 
results of the AFCAS registry suggest that uninterrupt-
ed OAC does not increase periprocedural complications 
during coronary stenting and is a simple and cost-effec-
tive alternative to conventional heparin bridging. 
Similar findings were obtained in the subanalysis of 
the WOEST study [12]. The frequency of bleeding compli-
cations and MACCE were assessed in 241 patients treat-
ed with uninterrupted OAC and in 322 patients with BT. 
Radial access was more common in the uninterrupted 
OAC group. Moreover, the periprocedural use of LMWH 
(30% vs. 16%, p < 0.001) and GP IIb/IIIa inhibitors (14% 
vs. 3%, p < 0.001) was significantly lower in the uninter-
rupted OAC group, whereas the unfractionated heparin 
(UFH) bolus was given more frequently (90% vs. 94%, 
p < 0.001). The periprocedural INR was higher in the un-
interrupted OAC group (2.5 vs. 1.5, p < 0.001). The length 
of hospitalization after PCI was the same for both groups 
after elective PCI (median 1 day), but was longer in ACS 
patients in the uninterrupted OAC group (medians 3 vs. 
2 days). After 30 days, as well as after one year, there 
were no differences in bleeding events (p = 0.51, p = 
0.12, respectively). After 1 year, MACCE tended to be less 
frequent in the uninterrupted OAC group (12% vs. 16%, 
p = 0.16). Additionally, adjustment with a  propensity 
score revealed no significant differences. Periprocedural 
INR was not associated with bleeding or MACCE. Also the 
WOEST substudy indicates that in patients treated with 
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long-term OAC who undergo PCI, periprocedural continu-
ation of OAC is safe and effective.
Importantly, despite a  significantly higher value of 
periprocedural INR, uninterrupted OAC with VKA did not 
increase the rate of bleeding complications at all. More-
over, in the AFCAS substudy BT was associated with 
a  higher rate of access-site bleeding, whereas in both 
AFCAS and WOEST substudies uninterrupted OAC was 
associated with similar rates of stent thrombosis. An ad-
vantage of uninterrupted VKA therapy during PCI might 
be avoidance of potential thromboembolic complications 
associated with a period of subtherapeutic anticoagula-
tion and elimination of a period of a potential transient 
prothrombotic state due to protein C and S suppression 
after warfarin re-initiation. Moreover, uninterrupted OAC 
with VKA may offer an economic benefit related to short-
er hospitalization. Based on the above-presented results 
in patients with therapeutic INR 2–3.0 during PCI dual an-
tiplatelet therapy, no additional heparin bolus and radial 
access seem the first choice strategy [10, 13]. An addi-
tional UFH bolus or bivalirudin (especially at high risk of 
bleeding) may be considered in patients with INR < 2.0, 
complex lesion PCI or prolonged procedure; however, gly-
coprotein IIb/IIIa inhibitors should be avoided (Figure 1).
The experience with performing PCI in patients treat-
ed with NOAC is limited. In a small, phase IIa, random-
ized study, 50 stable patients on standard DAPT were 
randomized (2 : 2 : 1) to either pre-procedural dabigatran 
110 mg BID or 150 mg BID or standard intraprocedural 
UFH [14]. Following PCI, a significant increase in the level 
of prothrombin 1.2 fragments and thrombin-antithrom-
bin complexes, markers of thrombin generation in circu-
lating blood, were observed in the combined dabigatran 
group as compared to those immediately before the start 
of PCI. In contrast, in the control group no such increase 
was noted. Moreover, 5 out of 40 patients required bail-
out anticoagulation in the dabigatran group, of whom 
four experienced a procedural MI, versus one out of 10 in 
the UFH group. One minor access-site bleeding occurred 
in the dabigatran group. Based on these preliminary re-
sults, dabigatran treatment provides an insufficient an-
ticoagulation effect during PCI [14]. In a  similar study, 
108 stable CAD patients on DAPT undergoing elective PCI 
were randomized (2 : 2 : 2 : 1) to a short treatment course 
of rivaroxaban 10 mg, rivaroxaban 20 mg, rivaroxaban 
10 mg plus UFH or standard periprocedural UFH [15]. Ri-
varoxaban effectively suppressed blood coagulation ac-
tivation as measured by prothrombin 1.2 fragments and 
thrombin-antithrombin complexes after elective PCI and 
stenting without an increased bleeding rate. 
In the TAO trial [16], 13,229 patients were random-
ized either to a bolus of otamixaban, a synthetic intra-
venous direct factor Xa inhibitor, followed by one of two 
infusion doses of 0.100 or 0.140 mg/kg/h or to UFH 
plus eptifibatide, at the time of PCI. The final otamix-
aban infusion rate selected after interim analysis was 
Patient on NOAC 
or VKA
For all patients recommended:
–  Radial access
–  New generation DES
–  Start aspirin at the first medical 
contact
–  Start clopidogrel just before PCI
–  Avoid more potent P2Y
12
 inhibitors
–  GP IIb/IIIa inhibitors only in bail-out 
complication 
–  Proton pump inhibitor
Urgent intervention 
required  
(STEMI  
or high-risk NSTEMI)
Blood sampling without waiting for 
the results
VKA patient:
–  INR < 2.0 or unknown → low-dose 
of UFH or enoxaparin or full dose 
of bivalirudin
–  INR > 2.5 → no additional  
anticoagulants during PCI
NOAC patient:
–  Half dose of UFH or enoxaparin or 
full dose of bivalirudin
Renal function, blood morphology, 
creatinine, INR, APTT
VKA patient:
–  INR > 2.5 → no additional  
anticoagulants during PCI
–  INR < 2.0 → half-dose of UFH 
or enoxaparin or full dose of 
bivalirudin
NOAC patient:
–  Postpone intervention at least 24 h 
after last dose
–  Then UFH or enoxaparin or  
bivalirudin 
Urgent intervention 
not required  
(elective PCI  
or low-risk NSTEMI)
Figure 1. Periprocedural antithrombotic management
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0.140 mg/kg/h. In the TAO trial 91% of patients received 
thienopyridine, mostly clopidogrel, 99% underwent cor-
onary angiography, 65% PCI and 29% were treated con-
servatively. The primary efficacy outcome expressed as 
death or MI by day 7 occurred in 5.5% of patients ran-
domized to receive otamixaban and in 5.7% treated with 
UFH plus eptifibatide (p = 0.93). Procedural thrombotic 
complications during the index PCI were found in 4.0% 
and 4.6%, respectively. Prespecified subgroup analysis of 
the primary efficacy endpoint did not identify patients 
who benefited from otamixaban. The primary safety out-
come of Thrombolysis in Myocardial Infarction (TIMI) ma-
jor or minor bleeding by day 7 was significantly increased 
by otamixaban (3.1% vs. 1.5%, p < 0.001).
Because of lack of evidence for safety and efficacy of 
NOAC during PCI, in elective patients it is recommended 
to discontinue NOAC at least 24 h before the procedure 
and to conduct periprocedural anticoagulation according 
to the local practice including UFH, enoxaparin or bivali-
rudin and a loading dose of DAPT with aspirin and clopi-
dogrel (Figure 1) [17, 18]. Only in case of stent throm-
bosis while on clopidogrel, aspirin and OAC should more 
potent P2Y12 inhibitors, namely ticagrelor or prasugrel, 
be considered [19, 20]. The management in very low risk 
ACS patients might be similar to elective procedures.
In STEMI or high risk NSTEMI patients to whom im-
mediate PCI is strongly recommended regardless on the 
time elapsed since the last dose of VKA or NOAC, apart 
from a  radial approach and loading dose of DAPT with 
aspirin and clopidogrel, it is recommended to use addi-
tional low-dose parental anticoagulation, i.e. UFH, enoxa-
parin or a full dose of bivalirudin. Because of uncertainty 
about the interpretation of routine coagulation tests in 
patients on NOAC, an anticoagulation strategy based on 
their results should not be used. 
In patients with NSTEMI who do not require imme-
diate intervention, the optimal time for the procedure 
might be established after measurement of routine co-
agulation tests, creatinine clearance and discontinuation 
of VKA or NOAC. In such ACS patients with delayed inter-
vention of more than 12 h after the last dose of NOAC, 
fondaparinux or enoxaparin can be initiated. In all pa-
tients on OAC and DAPT, proton pump inhibitors should 
be promptly implemented [1, 17, 18, 21].
Long-term treatment of patients on OAC 
after revascularization
The oral anticoagulation should be started after elec-
tive PCI is completed or in the case of ACS after patient 
stabilization, if there is no vascular complication at the 
access site. In de novo AF the choice of anticoagulant 
depends on several factors. The candidates for warfarin 
therapy are patients unable to afford newer anticoagu-
lants, with mechanical heart valves, creatinine clearance 
< 30 ml/min, severe hepatic disease, and also those with 
frequent missed doses, multiple co-medications that 
may interact with NOAC, extremes of body weight, par-
ticularly those over 150 kg, and patients with question-
able adherence. In the majority of patients NOAC might 
be considered. Especially rivaroxaban or apixaban are 
preferred in patients with renal impairment or dyspepsia, 
apixaban or VKA after recent gastro-intestinal bleeding 
and dabigatran after ischemic stroke on warfarin [1, 22, 
23]. In patients with AF on anticoagulation before PCI, 
there is no evidence for benefits from switching to VKA 
or NOAC. Only in patients in whom ACS is caused by cor-
onary artery embolization by thrombo-embolic material 
does an anticoagulant switch seem reasonable.
Currently it is unknown whether antiplatelet ther-
apy with NOAC is safer and more effective in patients 
after PCI for ACS or stable CAD than antiplatelet therapy 
in combination with VKA. Because addition of any type 
of single antiplatelet therapy, especially DAPT, to VKA or 
NOAC anticoagulation significantly increases the risk of 
major bleeding, the European guidelines recommend 
maintaining the INR within 2.0–2.5 during triple or dual 
therapy with VKA and reducing doses of NOAC [17, 18].
The effectiveness and safety of adding antiplatelet 
therapy to VKA in AF patients with stable CAD defined as 
at least 12 months from an ACS was examined in a large 
Danish registry [24]. Among 8700 patients followed for 
a median of 3.3 years, the risk of MI, coronary death or 
thromboembolism was similar for VKA plus aspirin, VKA 
plus clopidogrel and VKA monotherapy, whereas the risk 
of bleeding significantly increased by 1.5 times when as-
pirin or by 1.84 times when clopidogrel was added to VKA. 
A high risk of major bleeding with triple therapy in AF 
patients was also confirmed after acute MI [25] and fol-
lowing MI and coronary intervention [16]. In 40 812 pa-
tients from the Danish nationwide registry during a mean 
follow-up of 477 days, 4.6% of patients were admitted to 
hospital due to bleeding complications [22]. With aspirin 
as reference, adjusted hazard ratios for bleeding were 
1.33 for clopidogrel, 1.23 for VKA, 1.47 for aspirin plus 
clopidogrel, 1.84 for aspirin plus VKA, 3.52 for clopidogrel 
plus VKA, and 4.05 for triple therapy. There was a slightly 
higher bleeding risk with clopidogrel plus OAC than with 
aspirin plus OAC, as prior data had indicated [15]. In turn, 
in 11 480 patients with AF who were admitted with MI 
or for PCI, a 6.3% rate of bleeding events, including 0.7% 
fatal, was recorded within 1-year follow-up [26]. Bleeding 
risk with triple therapy exposure versus VKA plus one an-
tiplatelet agent was significantly increased by 1.47 within 
the first 90 days and by 1.36 between 90 and 360 days. Si-
multaneously, no significant difference in thromboembolic 
risk was observed for triple therapy versus VKA combined 
with one antiplatelet agent.
A recent meta-analysis of seven randomized trials in-
cluding ACS patients showed that the addition of NOAC 
to DAPT more than doubled the risk of major bleeding 
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as compared to DAPT. On the other hand, adding NOAC 
to aspirin increases the major bleeding risk by 80% [27]. 
Simultaneously, NOAC reduced the incidence of MACE by 
13% when added to DAPT and by 30% if added to aspirin. 
To date, only two trials have randomly assigned pa-
tients requiring chronic anticoagulation and undergoing 
PCI to triple therapy versus dual therapy. In the WOEST 
trial [28], almost 70% of patients received OAC because 
of AF, but only a minority of patients had an ACS. Bleed-
ing episodes were observed in 19.4% of patients receiv-
ing VKA and clopidogrel and in 44.4% of those receiving 
VKA, clopidogrel and aspirin continued for a whole year 
(p < 0.0001). Simultaneously, the combined endpoint of 
death, MI, stroke, target-vessel revascularization and 
stent thrombosis was reported in 11.1% of patients in 
the dual therapy group and 17.6% in the triple therapy 
group (p = 0.025), and all-cause mortality at 1 year was 
estimated at 2.5% vs. 6.3% (p = 0.027), respectively. Al-
though there are no data on how aspirin and VKA would 
have performed, dual therapy with VKA and clopidogrel 
seems to be safer and more efficient as compared with 
triple therapy. The investigators of the ISAR-TRIPLE study 
investigated whether shortening the duration of clopi-
dogrel therapy from 6 months to 6 weeks after DES im-
plantation is associated with a superior clinical outcome 
in 614 patients mostly with stable CAD (67%) receiving 
concomitant aspirin and OAC [29]. The primary endpoint 
composed of death, MI, definite stent thrombosis, stroke, 
or TIMI major bleeding at 9 months occurred in 9.8% of 
patients in the 6-week group compared with 8.8% in 
the 6-month group (p = 0.63). There were no signifi-
cant differences in either major bleeding (5.3% vs. 4.0%, 
p = 0.44) or thrombotic (4.0% vs. 4.3%, p = 0.87) events 
between the two strategies. Six weeks of triple therapy 
was comparable to 6 months with respect to net clinical 
outcomes.
The prospective, multicenter, observational AFCAS 
(n = 914) registry [30] demonstrated that at 1-year fol-
low-up there was no difference among patients treated 
with triple therapy of VKA, aspirin, and clopidogrel versus 
DAPT vs. VKA plus clopidogrel in the propensity score-ad-
justed major adverse cardiac or cerebrovascular events 
(22% vs. 20% vs. 18%, respectively, p = 0.72). There was 
also no difference between groups regarding all-cause 
mortality (11% vs. 11% vs. 7%, respectively, p = 0.54) or 
major bleeding (10% vs. 12% vs. 7%, p = 0.43).
The issue regarding optimal combination of antico-
agulation with NOAC versus VKA with antiplatelet agents 
in AF patients after PCI with stenting will be hopefully 
provided by ongoing clinical trials (Table I). The time of 
combined antithrombotic and antiplatelet therapy after 
PCI depends on: i) indication for intervention (ACS, sta-
ble CAD), ii) stent type (preferred new-generation DES, 
BMS), iii) risk of bleeding (according to the HASBLED 
Table I. Ongoing clinical trials regarding optimal combination of anticoagulation with NOAC versus VKA with 
antiplatelet agents in AF patients after PCI with stenting
Trial acronym/status N Trial aim/hypothesis Study arms
RE-DUAL PCI/recruiting 2800 To study non-inferiority of each dose of dabiga-
tran arm when compared to warfarin in terms of 
safety determined by major bleeding and clinical-
ly relevant non-major bleeding events according 
to the modified ISTH classification
1. 110 mg dabigatran BID plus clopidogrel or tica-
grelor
2. 150 mg dabigatran BID plus clopidogrel or tica-
grelor
3. A triple antithrombotic therapy of warfarin plus 
clopidogrel or ticagrelor plus low-dose aspirin 
(< 100 mg OD)
PIONEER AF PCI/study 
completed
2129 To evaluate the safety of three different treatment 
strategies.
Safety in this trial is determined by significant 
bleeding as a composite of TIMI major bleeding, 
minor bleeding, and bleeding requiring medical 
attention
1. 15 mg rivaroxaban OD or 10 mg for subjects 
with moderate renal impairment plus clopido-
grel, prasugrel or ticagrelor
2. 2.5 mg rivaroxaban BID plus low-dose of aspirin 
and clopidogrel, prasugrel or ticagrelor followed 
by 15 mg rivaroxaban OD plus low-dose aspirin
3. VKA treatment strategy (target INR 2.0–3.0) 
plus low-dose aspirin and clopidogrel, prasu-
grel or ticagrelor followed by VKA plus low-dose 
aspirin for 12 months
AUGUSTUS/recruiting 4600 To determine whether apixaban is safer than VKA 
given for 6 months in terms of bleeding in AF pa-
tients with ACS or PCI with stent implantation 
within the prior 14 days. The primary outcome 
measure is time to first occurrence of major or 
clinically relevant non-major bleeding according 
to the ISTH classification
Randomization in a 2 × 2 factorial design to re-
ceive apixaban 5 mg OD or 2.5 mg BID, with or 
without aspirin, versus a VKA, with or without 
aspirin. 
All patients are receiving P2Y
12
 inhibitors
EVOLVE AF PCI/accepted 
by institutional board to 
start recruitment
Not determined yet Treatment strategies with edoxaban are planned
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score or other bleeding scores) and iv) risk of thrombo-
embolic complications (according to the CHA2DS2-VASc 
score). Taking together available data, triple therapy 
should be kept as short as possible, 1 month after PCI 
for stable CAD and no longer than 6 months after an 
ACS. Then up to 12 months OAC and single antiplate-
let therapy (SAPT) should be maintained. It remains 
unclear which would be that SAPT. The results of the 
WOEST trial suggest that clopidogrel might be preferred 
in the future. Currently there is no evidence to support 
the use of prasugrel or ticagrelor in combination with 
OAC. After 1 year following PCI, in patients with stable 
vascular status defined as no recurrent ACS or no repeat 
revascularization, anticoagulation in monotherapy may 
be continued. Figure 2 summarizes previous recommen-
dations [1, 15, 16].
In the case of high risk of bleeding or current bleeding 
and implantation of new generation DES (Xience, Reso-
lute) DAPT may be shortened to one month. It is worth 
remembering that in this group of patients left atrial ap-
pendage closure may also be considered [31]. In all pa-
tients on dual or triple therapy proton pump inhibitors 
should be implemented.
Optimal stent management
In the above-mentioned ISAR-TRIPLE trial [29], PCI 
with stenting in mostly stable CAD and AF patients with 
6-week triple anticoagulation therapy with aspirin, clopi-
dogrel and VKA was comparable with 6-month triple anti-
coagulation therapy with respect to net clinical outcomes. 
More than 90% received new-generation DES (38.5% ever-
olimus-eluting stents (EES), 16.1% biodegradable polymer 
Baseline indication for PCI
***
ACS
**
***
Stable CAD
*
***
ACS
**
***
Stable CAD
*
Bleeding risk
1 month
6 months
12 months
Low High
Patient on NOAC/VKA after PCI
  (NOAC or VKA) + ASA + CLOP 
*May be considered (NOAC or VKA) + (ASA or CLOP), if CHA
2
DS
2
-VASC 1 (men) or 2 (women) and elevated risk of bleeding or **no stent 
implantation
  (NOAC or VKA) + (ASA or CLOP)
  NOAC or VKA 
***May be considered NOAC/VKA + (ASA or CLOP) if high coronary risk (stenting of the left main/proximal left anterior descending/proxi-
mal bifurcation) and acceptable risk of bleeding
The dose of rivaroxaban 15 mg OD, apixaban 2.5 mg BID, edoxaban 30 mg OD or dabigatran 110 mg BID during triple/dual antithrombotic ther-
apy according to the practical guide of the European Heart Rhythm Association [1]. It is not specified by the current atrial fibrillation guidelines 
of the ESC [17].
Figure 2. Long-term antithrombotic management
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Biolimus-eluting stents (BES), 16% biodegradable polymer 
sirolimus-eluting stents (SES), 11% zotarolimus-eluting 
stents (ZES) and 11% probucol SES). However, the trial 
was not specifically powered to detect differences in the 
individual components of the primary endpoint.
The knowledge about appropriate stent choice comes 
from several trials evaluating short-term DAPT in patients 
without an indication for OAC. Two randomized trials, 
RESET (REal Safety and Efficacy of 3-month dual anti-
platelet Therapy following Endeavor zotarolimus-eluting 
stent implantation) [32] and OPTIMIZE (Optimized Dura-
tion of Clopidogrel Therapy Following Treatment with the 
Zotarolimus-Eluting Stent in Real-World Clinical Practice) 
[33], evaluated 3 vs. 12 months of DAPT. In these two 
trials the prevalence of diabetes mellitus was 32% and 
43% had ACS. In these two trials stent thrombosis was 
reported in 0.6% of patients with either 3- or 6-month 
DAPT, whereas clinically significant bleeding was report-
ed in 0.6% and 0.9%, respectively. 
Five randomized trials have evaluated 6-month vs. 
either 12-month DAPT – ISAR-SAFE (Safety and Efficacy 
of Six Months Dual Antiplatelet Therapy After Drug-Elut-
ing Stenting) [34], ITALIC (Is There A  Life for DES After 
Discontinuation of Clopidogrel) [35], SECURITY (Second 
Generation Drug-Eluting Stent Implantation Followed by 
Six- Versus Twelve-Month Antiplatelet Therapy) [36], and 
EXCELLENT (Efficacy of Xience/Promus Versus Cypher 
to Reduce Late Loss After Stenting) [37] – or 24-month 
DAPT (PRODIGY (Prolonging Dual Antiplatelet Treatment 
After Grading Stent-Induced Intimal Hyperplasia Study)) 
[38]. Second-generation stents were used in all patients 
in the ITALIC and SECURITY trials. In the EXCELLENT and 
ISAR-SAFE trials, a  second-generation DES was used in 
75% and 88% of patients, respectively. In the PRODIGY 
trial, every 25% of patients received ZES, EES, BMS and 
paclitaxel-eluting stents (PES). 74.3% of patients had an 
ACS in the PRODIGY trial, 52% in ISAR-SAVE and about 
50% in EXCELLENT, ITALIC and SECURITY.
A  meta-analysis of 6 randomized trials with short-
term DAPT (3 or 6 months) versus long-term DAPT (12 or 
24 months) showed that compared with 12- or 24-month 
DAPT, short-term DAPT had an overall higher rate of stent 
thrombosis (odds ratio (OR) = 1.71, p = 0.001) [39]. The 
effect of short-term DAPT on stent thrombosis was at-
tenuated with the use of second-generation DES as 
compared with the use of first-generation DES. Stent 
thrombosis rates with second-generation DES were 0.6% 
vs. 0.4%, whereas with first-generation DES the rates 
were 2.4% vs. 0.6%. There was a significant interaction 
between DES generation and DAPT treatment duration 
(p = 0.008). Short-term DAPT had an overall lower risk of 
clinically significant bleeding (OR = 0.63; p < 0.001) and 
also a numerically lower all-cause mortality rate (2.0% vs. 
2.2%, p = 0.073). It was found that for each stent throm-
bosis event averted by prolonging DAPT, an excess of 2.1 
clinically significant bleeding events would be expected.
Recommendations for BMS implantation in patients 
who require triple therapy are lacking and differ between 
centers due to the paucity of reliable data. The current 
guidelines are inconsistent. According to the myocardial 
revascularization guidelines of the European Society of 
Cardiology (ESC) [40], new-generation DES are preferred 
over BMS in patients at low bleeding risk (HAS-BLED 
score ≤ 2), whereas in high bleeding risk patients (HAS-
BLED score ≥ 3) the choice between BMS and new-gener-
ation DES needs to be decided on an individual basis. On 
the other hand, according to the practical guide of Euro-
pean Heart Rhythm Association [1] new generation DES 
or BMS are recommended to shorten the duration of the 
triple therapy. Recently, it was shown that in patients at 
high risk of bleeding or thrombosis, ZES combined with 
an abbreviated, tailored DAPT regimen resulted in a lower 
risk of 1-year death, MI or target vessel revascularization 
as compared with BMS [41]. Undoubtedly bioresorbable 
stents should be avoided in patients requiring OAC due 
to the need for prolonged DAPT [42, 43].
The optimal duration of DAPT with second-gener-
ation DES outside ACS still remains to be established. 
However, the timing of interruption of a  thienopyridine 
can be as short as 3 or 6 months after stent implantation. 
The results indicate that in the case of ZES clopidogrel 
discontinuation may be safely done after 3-month treat-
ment with DAPT.
Bleeding management
Bleeding complications remain an important issue 
during long-term OAC. The results of a prespecified me-
ta-analysis of all 71,683 AF patients included in the RE-LY, 
ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials 
[44] showed that as compared with warfarin, NOAC 
significantly reduced events of intracranial hemorrhage 
from 0.66% to 0.32% (p < 0.0001), but increased gas-
trointestinal bleeding from 0.92% to 1.17% (p = 0.04). 
Moreover, in comparison to warfarin, fatal bleeding risk 
was reduced with all NOAC. The reduction with apixaban 
was from 0.19% to 0.16%, with dabigatran from 0.3% to 
0.21%, with edoxaban from 0.84% to 0.38%, and with 
rivaroxaban from 0.77% to 0.38% [45]. Also case fatal-
ity due to major bleeding was reduced with dabigatran 
(3.37% vs. 4.23%), edoxaban (7.74% vs. 11.23%) and 
rivaroxaban (6.84% vs. 14.25%) but not with apixaban 
(4.59% vs. 3.68%) as compared to warfarin. 
As expected, concomitant antiplatelet drugs increased 
the risk of major bleeding in AF patients receiving dabig-
atran as compared to those without antiplatelet agents 
(4.4% vs. 2.6%), irrespective of the dabigatran dose [46]. 
In those who used antiplatelet agents, the absolute risk 
of bleeding was lowest with dabigatran 110 mg twice 
a day (BID), followed by dabigatran 150 mg BID and war-
farin, with rates of 3.9%, 4.4%, and 4.8% per year, respec-
tively. Also the risk of major bleeding was higher among 
Jarosław Zalewski et al. Antithrombotic management after PCI in patients requiring (N)OAC
297Advances in Interventional Cardiology 2016; 12, 4 (46)
patients who received dual antiplatelets (HR = 2.31) than 
among patients who only received a single antiplatelet 
(HR = 1.60) (p for trend < 0.001) in comparison to pa-
tients without antiplatelet therapy. A recently published 
subanalysis of 14,171 patients enrolled in the ROCKET-AF 
trial [47] showed that PCI occurred infrequently in 1.1% of 
patients with AF during a median 806 days of follow-up. 
DAPT of more than 30 days was used in 37%, single 
antiplatelet therapy in 34%, and the majority of patients 
(81%) remained on anticoagulation after PCI. Rates of 
both thrombotic and bleeding events were high in the 
post-PCI period, and most of them occurred within 
6 months. In patients on rivaroxaban versus warfa-
rin, rates of stroke/systemic embolism were 5.0% vs. 
4.1%/100 patient-years and major bleeding events 
15.0% vs. 8.1/100 patient-years, respectively.
In patients with bleeding during OAC it is neces-
sary to determine in what circumstances the event oc-
curred, how much time elapsed since the intake of the 
last dose of anticoagulant agent, whether the patient 
suffers from chronic kidney disease and which concom-
itant drugs are taken concomitantly. It is also recom-
mended to sample the patient for blood cell counts, 
serum creatinine, prothrombin time (PT) or INR, if he 
or she is on VKA, and activated partial thromboplastin 
time (APTT). Regarding NOAC, rivaroxaban can prolong 
PT (and increase the automatically calculated INR) and 
APTT, whereas dabigatran increases APTT, thrombin 
time (TT), and ecarin clotting time, with a slight increase 
in PT-INR at high concentrations and with a weak cor-
relation with their plasma concentration measured di-
rectly by the high-performance liquid chromatography 
(HPLC)-tandem mass spectrometry [48–53]. Currently, 
routine laboratory monitoring of NOAC concentrations 
using clot-based assays is not recommended [50, 54]. 
However, there are clinical situations including bleeding 
complications in which measurements of the anticoag-
ulant effect of NOAC are desirable. The most common 
tests used for this purpose are calibrated quantitative 
anti-factor-Xa assays for factor Xa inhibitors or the 
Hemoclot assays measuring dilute TT in patients on 
dabigatran. These tests may not be readily available, 
but in some labs they are performed 24/7 and their re-
sults are available up to 2 h [51, 52, 55].
In patients with minor bleeding usually local com-
pression is enough and the next doses of anticoagulant 
should be omitted depending on the bleeding intensity 
and patient status. In patients with normal renal func-
tion, hemostasis normalizes within 12–24 h after the last 
dose of NOAC. This time can be prolonged even more 
than 48 h in patients with severe chronic kidney disease. 
Patients with moderate to severe bleeding require addi-
tionally blood pressure monitoring, diuresis maintenance 
and, depending on patient status and laboratory param-
eters, fluid replacement, plasma, platelet or blood trans-
fusion and more invasive procedures, e.g. gastroscopy, 
colonoscopy or bronchoscopy. In patients who received 
NOAC within the last 2–4 h charcoal administration and/
or gastric lavage might be considered. Moreover, dabiga-
tran can be dialyzed, but there is still limited experience 
with this approach. 
In patients with life-threatening bleeding, reversal of 
the antithrombotic effect is indicated. In subjects on VKA, 
prothrombin complex concentrate (PCC) or, if unavailable, 
fresh frozen plasma and/or vitamin K, that require 24–48 h 
to achieve normal blood coagulation, should be admin-
istered in a  dose adjusted to the INR value. In terms of 
bleeding complications associated with dabigatran, it was 
shown that idarucizumab, a humanized antibody fragment 
which irreversibly binds dabigatran, administered as an in-
travenous dual bolus of 2.5 g, normalized elevated dilute TT 
and elevated ecarin clotting time in 88% to 98% of patients 
with gastrointestinal bleeding, intracranial hemorrhage, 
trauma or requiring immediate surgery within minutes 
after antidote administration [56]. Simultaneously, one 
thrombotic event was reported within 72 h after idaruci-
zumab administration in a patient to whom anticoagulants 
had not been reinitiated. Recently, it has been reported that 
andexanet alfa, an inactive recombinant human factor Xa 
which binds factor Xa inhibitors, administered as a bolus 
or as a bolus plus a 2-hour infusion, in healthy older vol-
unteers receiving either 5 mg of apixaban twice daily or 
20 mg of rivaroxaban daily, reduced anti-factor Xa activ-
ity by 94% or 92%, within 2 to 5 min after antidote ad-
ministration, respectively [57]. Simultaneously, a transient 
increase of D-dimer and prothrombin 1.2 fragments was 
observed, without serious adverse or thrombotic events. 
Until October 2016 solely idarucizumab has been approved 
by the US Food and Drug Administration and the Europe-
an Medicines Agency and is increasingly used worldwide 
[58]. Andexanet alfa is expected to be approved for clinical 
use at the end of 2017. However, the experience with both 
idarucizumab and andexanet alfa in patients with ACS 
and/or shortly after stent implantation is very limited.
If a specific antidote is not available, PCC, preferably 
30–50 U/kg body weight with another half dose if the 
effect is suboptimal, should be promptly administered 
in patients on NOAC with life-threatening bleeding. The 
proportion of patients who need such therapy due to se-
vere bleeding is about 5–10% of those with major bleed-
ing, mostly elderly individuals with renal impairment.
ACS as a primary indication for NOAC
Tremendous progress in invasive and pharmacologi-
cal therapy of MI is associated with reduction of 30-day 
mortality to 7.8% [59] and 12–13% after 6 months [60, 
61]. Despite high rates of implementation of the guide-
line recommended therapy including aspirin, clopidogrel 
up to 1 year after an ACS event [62] and statin, at 5 years 
19% of patients with STEMI died, 22% with NSTEMI and 
17% with unstable angina (UA) [63]. 
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Because DAPT, even with the use of more potent P2Y12 
inhibitors [64, 65], is insufficient to abolish the residual 
risk of long-term recurrence, there is clinical evidence 
for implementation of antithrombin strategies, targeting 
both attenuation of platelet activation and aggregation 
as well as suppression of thrombin generation and/or 
thrombin activity. Therefore, selective anticoagulants, 
direct thrombin inhibitors or factor Xa inhibitors, have 
been tested in the ACS population.
Direct thrombin inhibitors 
In the phase II, dose-escalation RE-DEEM trial, 1861 
STEMI (60%) and NSTEMI (40%) patients on DAPT were 
randomized within 14 days after the index event to treat-
ment with dabigatran in a dose of 50–150 mg BID, or pla-
cebo [66]. The primary outcome measure defined as the 
composite of major or clinically relevant minor bleeding 
during the 6-month treatment period occurred in 3.5, 4.3, 
7.9 and 7.8% in the respective 50, 75, 110 and 150 mg 
BID dabigatran groups (p < 0.001 for trend), compared 
with 2.2% in the placebo group. Female gender and age 
> 75 years were associated with a higher rate of bleeding 
in patients receiving the two highest dabigatran doses. 
In terms of efficacy issues, death, MI or stroke oc-
curred in 4.6% of patients treated with 50 mg of dabig-
atran, in 4.9% with 75 mg, 3.0% with 110 mg, and 3.5% 
with a  dabigatran dose of 150 mg as compared with 
3.5% in the placebo group [48]. In patients receiving dab-
igatran, median D-dimer levels were 37% and 45% lower 
at weeks 1 and 4, respectively, as compared with patients 
in the placebo group (p < 0.001).
Direct Xa inhibitors
The safety and efficacy of apixaban administered up 
to 7 days after either STEMI or moderate- or high-risk 
NSTEMI/UA have been tested in the two APPRAISE tri-
als [67, 68]. The phase II APPRAISE study compared four 
apixaban doses of 5 mg twice daily, 10 mg once daily, 
10 mg twice daily or 20 mg once daily with placebo [59]. 
The enrolment to the two highest doses of apixaban was 
discontinued because of an excessive rate of bleeding. 
Of the 1715 patients randomized, 65% underwent PCI 
before enrolment, 76% received clopidogrel and aspirin, 
65% were diagnosed with STEMI, 30% with NSTEMI and 
8% with UA. Over a 6-month treatment, the primary out-
come measure expressed as major or clinically relevant 
non-major bleeding according to the ISTH was found in 
5.7% of patients with apixaban 2.5 mg twice daily (p = 
0.09) and in 7.9% with apixaban 10 mg once daily (p = 
0.005) vs. 3.0% in the placebo group. 
A dose-related increase in bleeding and a  trend to-
ward a reduction in ischemic events with the addition of 
apixaban to antiplatelet therapy in patients with a recent 
ACS was verified in the APPRAISE-2 study [68]. In this 
study 7392 patients were randomly assigned to receive 
either apixaban at a dose of 5 mg twice daily or place-
bo. The primary safety outcome expressed as TIMI major 
bleeding occurred in 1.3% of patients who received apix-
aban and in 0.5% of patients with placebo (p = 0.001). 
Importantly, intracranial bleeding (0.3% vs. 0.1%, p = 
0.03) and fatal bleeding (0.1% vs. 0%) were more fre-
quent in patients receiving apixaban as compared with 
placebo. During a median 6-month follow-up, the primary 
outcome of cardiovascular death, MI, or ischemic stroke 
occurred in 7.5% of patients receiving apixaban and in 
7.9% assigned to placebo (p = 0.51). Net clinical outcome 
expressed as a  composite endpoint of cardiovascular 
death, MI, ischemic or hemorrhagic stroke or fatal bleed-
ing was found in 8.0% of the apixaban group and in 8.1% 
of the placebo group (p = 0.80).
In both APPRAISE trials an increase in bleeding with 
apixaban was evident immediately after randomization. 
The addition of apixaban to antiplatelet therapy in high 
risk patients after an ACS significantly increased bleeding 
complications, without a  significant reduction in recur-
rent ischemic events.
In the ATLAS ACS-TIMI 46 phase II trial, 3491 patients 
stratified according to the use of aspirin or aspirin plus 
thienopyridine, 1–7 days after hospital admission for 
an ACS were randomized to placebo or rivaroxaban at 
doses of 5–20 mg given once or at the same total daily 
dose twice [69]. After 6-month follow-up, of 299 clinically 
significant bleeding events, 83% were categorized as re-
quiring medical attention, 11% as TIMI major, and 6% as 
TIMI minor bleeding. All those bleeding events occurred 
in a  dose-dependent manner with hazard ratios of 2.2 
for 5 mg, 3.4 for 10 mg, 3.6 for 15 mg, and 5.1 for 20 mg 
rivaroxaban daily doses (p < 0.0001) as compared to pla-
cebo. In the whole cohort, rates of the primary efficacy 
endpoint defined as death, MI, stroke, or severe recur-
rent ischemia requiring revascularization were 5.6% for 
rivaroxaban and 7.0% for placebo (relative risk reduction 
of 21%, p = 0.10). By exploratory analysis, a significant 
reduction in primary efficacy endpoint with rivaroxaban 
was observed in patients aged above 65 years by 53% 
(p for interaction = 0.007) and in patients with STEMI by 
42% (p for interaction = 0.042).
The results of the ATLAS ACS-TIMI 46 trial allowed se-
lection of the most favorable dose and dosing regimen 
of rivaroxaban in combination with aspirin or aspirin and 
thienopyridine, which was applied in the phase III ATLAS 
ACS2-TIMI 51 study [70]. This trial was designed to test 
whether inhibition of factor Xa with low-dose rivarox-
aban might improve cardiovascular outcomes in patients 
with a  recent ACS. 15 526 ACS patients were randomly 
assigned to twice-daily administration of either 2.5 mg or 
5 mg of rivaroxaban or placebo with a mean follow-up pe-
riod of 12 months. Rivaroxaban significantly reduced the 
primary efficacy endpoint of death from cardiovascular 
causes, MI, or stroke as compared with placebo (8.9% vs. 
10.7%, p = 0.008). For both the twice-daily 2.5-mg dose 
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(9.1% vs. 10.7%, p = 0.02) and the twice-daily 5-mg dose 
(8.8% vs. 10.7%, p = 0.03) significant improvement of the 
primary efficacy endpoint was found. The lower dose of 
rivaroxaban but not twice-daily 5 mg also reduced the 
rates of death from cardiovascular causes (2.7% vs. 4.1%) 
and from any cause (2.9% vs. 4.5%, p = 0.002 for both). 
Rivaroxaban also reduced the risk of in-stent thrombosis 
as compared with placebo (2.3% vs. 2.9%, p = 0.02). 
Compared with placebo, both rivaroxaban doses 
increased 3.5–4.5 times the risk of major bleeding not 
related to CABG (p < 0.001 for both) and 2.8–3.8 times 
the risk of intracranial hemorrhage (p < 0.05 for both), 
without a significant increase in fatal bleeding (0.3% vs. 
0.2%). In comparison of two rivaroxaban doses, signifi-
cantly lower rates of TIMI minor bleeding (0.9% vs. 1.6%, 
p < 0.05), TIMI bleeding requiring medical attention 
(12.9% vs. 16.2%, p < 0.001) and fatal bleeding (0.1% 
vs. 0.4%, p = 0.04) were found with the lower dose [70].
DAPT versus SAPT with NOAC after ACS
Although in the APPRAISE trial [67] patients receiving 
DAPT were younger and less frequently had renal insuffi-
ciency or cerebrovascular disease than patients receiving 
aspirin alone, the dose-related increase of bleeding with 
apixaban was more apparent in patients taking DAPT. As 
compared with placebo, among patients receiving clopi-
dogrel and aspirin the adjusted rate difference in major 
or clinically relevant bleeding was 2.2% for apixaban 
2.5 mg BID and 3.8% for apixaban 10 mg once daily (OD) 
and in patients on aspirin –0.7% and 0.8%, respectively. 
The incidence of cardiovascular death, MI, severe recur-
rent ischemia, or ischemic stroke was not significantly 
lower in patients receiving apixaban 2.5 mg BID (7.6%, 
p = 0.21) and 10 mg OD (6.0%, p = 0.07) as compared 
with placebo (8.0%). Although patients on both DAPT 
and aspirin alone tended to have lower rates of ischemic 
events with both apixaban doses, the incidence of com-
posite ischemic endpoint was about twice as low on DAPT.
In ATLAS ACS-TIMI 46 [69], across all rivaroxaban dos-
es (5–20 mg), the absolute rate of clinically significant 
bleeding was lower in patients receiving aspirin only 
(2.9–10.7%) than in patients on DAPT (11.7–16.0%, p < 
0.0001). In turn, compared with placebo, in patients with 
aspirin alone rivaroxaban reduced the risk of primary ef-
ficacy endpoint by 47%, but only by 1% in patients on 
DAPT (p for interaction = 0.034). In patients treated with 
aspirin only but not on DAPT, a significant reduction of 
death, MI and stroke with 5, 10 or 20 mg of rivaroxaban 
versus placebo was found (8.0%, 7.0% or 4.7% vs. 11.9%, 
respectively, p = 0.01 for trend).
The net clinical outcome associated with rivaroxaban 
defined as hazard ratio of death, MI, stroke, or TIMI ma-
jor bleeding, as compared with placebo in patients on 
aspirin only, was 0.57, and on DAPT 1.17. The respective 
hazard ratios assessed in participants with a  dose of 
2.5 mg or 5 mg twice daily were 0.59 in patients with 
aspirin and 0.85 in patients on DAPT [70].
Future perspectives for NOAC after ACS
Currently NOAC are not recommended for treatment 
of the acute phase of ACS. The role of NOAC in combi-
nation with more potent DAPT in secondary prevention 
after ACS is promising but requires further research. The 
safety and efficacy of rivaroxaban as compared with as-
pirin, in addition to a single antiplatelet P2Y
12 inhibitor – 
clopidogrel or ticagrelor – in subjects with a recent STEMI 
or NSTEMI are being tested in the ongoing GEMINI trial. 
There is also no evidence that prothrombotic genetically 
determined factors might affect the efficacy or safety of 
NOAC used in monotherapy or combination [71].
Summary
Available, mostly observational data indicate that in 
patients who require oral anticoagulation, both VKA and 
NOAC could be used with aspirin and clopidogrel follow-
ing PCI in MI and stable angina patients, but the optimal 
combination of anticoagulation with NOAC versus VKA 
with antiplatelet agents will hopefully be provided by on-
going clinical trials. The safety and efficacy of prasugrel 
and ticagrelor taken with oral anticoagulants also remain 
to be established in randomized trials; therefore the P2Y
12 
inhibitor clopidogrel on top of aspirin or without is now 
recommended to be used together with a VKA or NOAC. 
It is still unclear which dose of a NOAC in combination 
with antiplatelet agents and different stents should be 
used in this clinical setting and whether indeed NOAC 
are safer compared with VKA in such cardiovascular pa-
tients. Another controversial issue is whether or not to 
use oral anticoagulation in addition to antiplatelet ther-
apy for secondary prevention in patients with ACS. The 
safety and efficacy of prasugrel and ticagrelor taken with 
NOAC also remain to be established in randomized trials. 
To minimize bleeding risk, a tailored approach should be 
implemented in which the right agent will be prescribed 
to the right patient at the right dose and supported by 
regular clinical evaluation and laboratory testing, espe-
cially renal function. It is now unclear whether the reg-
ular full dose NOAC are safe as compared to previously 
recommended reduced doses of these agents. Observa-
tional studies and ongoing randomized controlled trials 
are likely to optimize dosage and duration of this com-
plex antithrombotic therapy in patients following PCI.
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